Testing effectiveness (Phase 2)UnknownNCT05819060What this trial is testingThe Efficacy and Safety of The Fuzuloparib Combination With BevacizumabWho this might be right forRecurrent Ovarian Cancer Fudan University 44
Large-scale testing (Phase 3)Study completedNCT01204749What this trial is testingTRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube CancerWho this might be right forFallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer Amgen 919
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07454018What this trial is testingIparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian CancerWho this might be right forRecurrent Ovarian CancerPlatinum-sensitive Ovarian Cancer The First Affiliated Hospital of Soochow University 45
Post-approval studies (Phase 4)Ended earlyNCT03164980What this trial is testingQoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian CancerWho this might be right forQuality of LifeOvarian CancerRecurrent Ovarian Carcinoma North Eastern German Society of Gynaecological Oncology 89
Early research (Phase 1)Study completedNCT01459380What this trial is testingPegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerWho this might be right forOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous Carcinoma+5 more National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)UnknownNCT04566952What this trial is testingAnlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerWho this might be right forOvarian CancerOvarian and Fallopian Tube Cysts and NeoplasmsNeoplasms by Site+16 more Xiaoxiang Chen 68
Early research (Phase 1)Ended earlyNCT03691376What this trial is testingGenetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerWho this might be right forPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+9 more Roswell Park Cancer Institute 4
Testing effectiveness (Phase 2)UnknownNCT05479487What this trial is testingFluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance TreatmentWho this might be right forRelapsed Ovarian Cancer Xiaohua Wu MD 132
Testing effectiveness (Phase 2)Ended earlyNCT00277290What this trial is testingStudy of XL999 in Patients With Previously Treated Ovarian CancerWho this might be right forOvarian Cancer Symphony Evolution, Inc. 24
Early research (Phase 1)Study completedNCT01281514What this trial is testingCarboplatin, PLD and Everolimus in Certain Gynecologic CancerWho this might be right forFallopian Tube CancerPeritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer Fox Chase Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT00004083What this trial is testingLiposomal Cisplatin in Treating Patients With Recurrent Ovarian CancerWho this might be right forOvarian Cancer NYU Langone Health
Testing effectiveness (Phase 2)Study completedNCT01001910What this trial is testingPemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerWho this might be right forRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma Albert Einstein College of Medicine 22
Testing effectiveness (Phase 2)WithdrawnNCT00369954What this trial is testingGemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or CarboplatinWho this might be right forFallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT05041257What this trial is testingMirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersWho this might be right forOvarian CancerPeritoneal CancerFallopian Tube Cancer AbbVie 79
Large-scale testing (Phase 3)Ended earlyNCT00189371What this trial is testingReinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or PeritoneumWho this might be right forEpithelial Ovarian Cancer, Fallopian Tube or PeritoneumPlatinum Sensitve RelapseAnemia AGO Study Group 300
Early research (Phase 1)Study completedNCT02092363What this trial is testingDose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian CancerWho this might be right forOvarian Cancer OncoMed Pharmaceuticals, Inc. 37
Large-scale testing (Phase 3)Active Not RecruitingNCT05445778What this trial is testingMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerWho this might be right forOvarian CancerPeritoneal CancerFallopian Tube Cancer AbbVie 520
Testing effectiveness (Phase 2)Study completedNCT01481701What this trial is testingA Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian CarcinomaWho this might be right forOvarian CarcinomaRelapse Jules Bordet Institute 90
Early research (Phase 1)Study completedNCT00002600What this trial is testingCombination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial CancerWho this might be right forFallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 23
Testing effectiveness (Phase 2)Study completedNCT01472783What this trial is testingVeliparib Monotherapy for Relapsed Ovarian Cancer With BRCA MutationWho this might be right forRecurrent, Epithelial Ovarian Cancer Vejle Hospital 49